Amputation

Imagine Pharma Launches the Imagine Pharma Foundation to Advance Metabolic Research with a Focus on Veterans

Retrieved on: 
Tuesday, January 23, 2024

PITTSBURGH, Jan. 23, 2024 /PRNewswire/ -- Imagine Pharma, a biotech company focused on furthering the commercialization opportunities related to its novel IMG-1 polypeptide across three distinct platforms: Oral Delivery, Therapeutics, and Regenerative Medicine, announced today the formation of The Imagine Pharma Foundation, a private not for profit charitable organization dedicated to advancing metabolic research to significantly impact the lives of those affected by diabetes, with a particular emphasis on serving veterans.

Key Points: 
  • The Imagine Pharma Foundation will collaborate with leading research institutions, pharmaceutical companies, healthcare providers, and other non-profit organizations, with a focus on four key areas: advancement of metabolic and diabetes research, increasing access to cutting-edge treatments for veterans and communities in need, supporting other non-profits focused on metabolic research and care and implementing education and awareness programs on diabetes prevention.
  • Diabetes is a major global health concern, affecting nearly 25 percent of the Department of Veterans Affairs (VA) patient population.
  • The disease is also the leading cause of blindness, end-stage renal disease, and amputation for VA patients.
  • "Through cutting-edge research, collaboration and education, we aim to play a leading role in advancing research and treatment for diabetes and other metabolic diseases to help improve outcomes for those with this disease."

SeaWorld Orlando Returns Mother-Daughter Manatee Pair to Florida Waters After More than a Year of Rehabilitation and 17,000+ Hours of Specialized Care

Retrieved on: 
Thursday, January 18, 2024

ORLANDO, Fla., Jan. 18, 2024 /PRNewswire/ -- Today, SeaWorld Orlando successfully returned Reckless and Churro, a mother and calf manatee duo, to Broward County in Florida after more than a year of incredible rehabilitation at its Rescue Center. The rehabilitation work included 12 lifesaving procedures and more than 17,000 hours of specialized care.

Key Points: 
  • The rehabilitation work included 12 lifesaving procedures and more than 17,000 hours of specialized care.
  • Reckless and Churro were rescued in Florida in May 2022 by the Florida Fish and Wildlife Conservation Commission (FWC) and SeaWorld after Reckless suffered a catastrophic boat strike.
  • Given Reckless' extensive injuries, the mother-daughter pair required over 17,000 hours of specialized care to keep them both healthy throughout the intensive rehabilitation process.
  • SeaWorld Orlando has the largest manatee rescue operation in the U.S., and one of only three critical care centers.

Lavior Partners with the ADA & Walmart to Bridge the Healthcare Disparities Gap and Deliver Affordable, Life-Changing Solutions for Those Living With Diabetes

Retrieved on: 
Tuesday, January 16, 2024

MIAMI, Jan. 16, 2024 /PRNewswire-PRWeb/ -- Lavior Pharma (Lavior), the exclusive company offering comprehensive over-the-counter diabetic wound and skin treatments, announces a partnership with the American Diabetes Association (ADA) to further its mission of providing life-changing solutions for those patients and communities most affected by diabetes. The ADA has endorsed Lavior's Diabetic Hydrogel Wound Dressing with its Better Choices for Life mark for their efficacy, evidence-based research and ability to manage associative complications of diabetes in the initial stages, saving thousands of lives annually. Lavior is dedicated to making its life saving products easily accessible and affordable to those most impacted by diabetes through retail stores nationwide, including Walmart. Working closely with local and state governments, Lavior is taking the lead in addressing this nationwide problem by bringing this issue to the forefront with reasonable solutions to reduce diabetic amputations, healthcare costs, and improve patients' lives.

Key Points: 
  • Lavior is dedicated to making its life saving products easily accessible and affordable to those most impacted by diabetes through retail stores nationwide, including Walmart.
  • "We aim to reduce diabetic amputations and bridge the gap to help heal stubborn wounds, leading to longer lifespans.
  • The ADA's Better Choices for Life program is designed to help consumers make better-informed choices about products related to diabetes care.
  • Lavior products are available in Walmart nationwide and on Walmart.com for less than $20 for a 30-day supply.

'I never lost a fight against a man': the story of the only woman to join Japan's notorious yakuza

Retrieved on: 
Wednesday, January 17, 2024

These are signs of affiliation to the yakuza – Japan’s notorious criminal syndicates.

Key Points: 
  • These are signs of affiliation to the yakuza – Japan’s notorious criminal syndicates.
  • Typically a woman involved with the yakuza might be an anesan, a boss’ wife who takes care of young affiliates and mediates between them and her husband.
  • But she went one step further – Nishimura is the only woman who has ever partaken in the sakazuki ceremony of exchanging sake cups.

Joining the gang

  • Her memories revolve around her authoritarian father and the bamboo stick he would use to discipline her.
  • Her life took a turn when one night she received a call: her friend was in a fight and needed help.
  • She joined alongside a cohort of male recruits, performing daily tasks, and eventually taking part in the group’s criminal activities.

Master of finger cutting

  • As an affiliate, she ran prostitution and drugs businesses, collected debts and mediated disputes between rival groups.
  • When she cut off her own little finger to apologise for a collective mistake in a ritual known as yubitsume, she realised she had a knack for it.
  • Members who could not go through with the amputation themselves would ask Nishimura to do it for them, garnering her the nickname of “master of finger cutting”.
  • She rejoined her old group, but meth had changed the boss that she adored, and in two years she left for good.

Life after crime

  • She found a job in the demolition business and a modest home where she now lives alone.
  • She lives a quiet life, trying to be accepted by the community and to help others.
  • Her story redefines the boundaries of gender roles and allegiance in the brutal world of Japanese organised crime – a unique journey of identity and belonging.


Martina Baradel receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement 101029138.

What is frostbite, what are the signs and how should we treat it?

Retrieved on: 
Wednesday, January 17, 2024

Thankfully, with the right preventative and protective measures, the human body can survive these icy temperatures.

Key Points: 
  • Thankfully, with the right preventative and protective measures, the human body can survive these icy temperatures.
  • Here’s what you need to know about identifying and treating the most common cold injury: frostbite.
  • However, despite our bodies’ inherent temperature controls, without the right protection, we might still be vulnerable to cold weather injuries.
  • For frostbite to occur, exposed body parts need to be subjected to a temperature that is below minus 0.55°C.
  • At this temperature it will take several hours for exposed skin to become frostbitten.
  • For example, temperatures in the -20s can cause frostbite on exposed skin in under 30 minutes.

Who does it affect?

  • However, with the global population beginning to live in harsher environments and an increase in winter and snow sports, this is likely to increase in the general population.
  • Reduced ability to sense the cold also increases the frostbite vulnerability of those who’ve had a stroke or have peripheral nerve damage.
  • The consumption of alcohol also reduces blood pressure, which may also reduce the amount of blood pumped to extremities.

Symptoms

  • Preserving the core body temperature is key to keeping the brain, heart, kidneys and lungs functioning and preventing hypothermia.
  • This cooling brings about tingling and numbness of the exposed areas, and skin flushes red or white as the body frantically tries to rewarm itself.
  • This initial stage is known as frostnip, and, although uncomfortable, leaves no permanent damage to tissues.

Treatment and prevention

  • For frostbite, immediate medical treatment should be sought – sadly the pain of recovery is often far worse than the injury.
  • Rewarming is the process of bringing the affected parts back to functioning body temperature.
  • However, where ice crystals have damaged tissue, blisters are common and the nerves become hypersensitive, causing excruciating pain.


Adam Taylor does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Reflow Medical Receives CE Mark for Bare Temporary Spur Stent System for Treating de novo or Restenotic Below-the-Knee (BTK) Lesions

Retrieved on: 
Tuesday, January 16, 2024

Reflow Medical, Inc., a developer of innovative medical devices focused on cardiovascular disease, announces it has received CE (Conformité Européenne) Mark certification in the European Union for the Bare Temporary Spur Stent System .

Key Points: 
  • Reflow Medical, Inc., a developer of innovative medical devices focused on cardiovascular disease, announces it has received CE (Conformité Européenne) Mark certification in the European Union for the Bare Temporary Spur Stent System .
  • The device is intended to treat de novo or restenotic lesions in the infrapopliteal arteries with a commercially available drug-coated balloon (DCB) to enhance drug absorption.
  • View the full release here: https://www.businesswire.com/news/home/20240116803175/en/
    The Bare Temporary Spur Stent System is a unique clinical solution known as Retrievable Stent Therapy, or RST.
  • The Bare Temporary Spur Stent System is a unique clinical solution intended to provide stent-like results while leaving no metal behind.

Challenged Athletes Foundation Joins In Motion Events for the First Official Inclusive Kids Marathon Mile at LEGOLAND® California Resort

Retrieved on: 
Wednesday, January 10, 2024

SAN DIEGO, CA, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Celebrating its 30th anniversary of empowering individuals through sports, the Challenged Athletes Foundation (CAF) has partnered with, Merlin’s Magic Wand Foundation , and In Motion Events to present the first official inclusive Kids Marathon Mile on Saturday, January 13, 2024 at LEGOLAND® California Resort.

Key Points: 
  • SAN DIEGO, CA, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Celebrating its 30th anniversary of empowering individuals through sports, the Challenged Athletes Foundation (CAF) has partnered with, Merlin’s Magic Wand Foundation , and In Motion Events to present the first official inclusive Kids Marathon Mile on Saturday, January 13, 2024 at LEGOLAND® California Resort.
  • Hundreds of children with and without physical disabilities will race one mile together through LEGOLAND® California as part of the Carlsbad Marathon race weekend.
  • In collaboration with Merlin’s Magic Wand Foundation, CAF is proud to bring this unique and exclusive opportunity for participants to enjoy at LEGOLAND® California.
  • Garcia-Tolson began his running journey as a youth athlete at this same race when it was formerly known as the Carlsbad Kids Marathon Mile.

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

Retrieved on: 
Wednesday, January 10, 2024

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn't just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1's reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer's and Parkinson's to drug addiction, clinical trials are painting a stunning picture of GLP-1's versatility. And it doesn't stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW), that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

Key Points: 
  • GLP-1 agonists are among the hottest drugs in healthcare, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Lexaria Bioscience has developed DehydraTECH drug-delivery platform, which is being shown to improve pharmacokinetics of orally administered drugs.
  • Lexaria issued final data from the pilot study and is planning for multiple human and animal studies early in 2024.
  • Uncontrolled blood sugar dramatically increases the risk of devastating comorbidities, including kidney disease, vision loss, amputations, heart attacks, strokes and early death.

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

Retrieved on: 
Wednesday, January 10, 2024

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn't just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1's reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer's and Parkinson's to drug addiction, clinical trials are painting a stunning picture of GLP-1's versatility. And it doesn't stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW), that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

Key Points: 
  • GLP-1 agonists are among the hottest drugs in healthcare, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Lexaria Bioscience has developed DehydraTECH drug-delivery platform, which is being shown to improve pharmacokinetics of orally administered drugs.
  • Lexaria issued final data from the pilot study and is planning for multiple human and animal studies early in 2024.
  • Uncontrolled blood sugar dramatically increases the risk of devastating comorbidities, including kidney disease, vision loss, amputations, heart attacks, strokes and early death.

Niterra Leads $10M Growth Funding Round for Imbed Biosciences

Retrieved on: 
Monday, January 8, 2024

Niterra today announced its participation in the $10M convertible debt financing for Imbed Biosciences, Inc. (Imbed) , a tissue engineering company developing advanced biomaterials for soft-tissue repair.

Key Points: 
  • Niterra today announced its participation in the $10M convertible debt financing for Imbed Biosciences, Inc. (Imbed) , a tissue engineering company developing advanced biomaterials for soft-tissue repair.
  • View the full release here: https://www.businesswire.com/news/home/20240108469239/en/
    Imbed Biosciences has developed the world’s first and only fully-synthetic and antimicrobial wound matrix, which is FDA-cleared.
  • The antimicrobial matrix provides a healing environment conducive to tissue growth and suppresses the growth of microbes and biofilms.
  • With this latest round of financing, Imbed Biosciences will further establish its position as the leading developer of advanced devices for the management of burns, wounds and soft-tissue repair.